Human Anti-A[beta] IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide

Soluble non-fibrillar assemblies of amyloid-beta (A[beta]) and aggregated tau protein are the proximate synaptotoxic species associated with Alzheimer's disease (AD). Anti-A[beta] immunotherapy is a promising and advanced therapeutic strategy, but the precise A[beta] species to target is not yet known. Previously, we and others have shown that natural human IgGs (NAbs) target diverse A[beta] conformers and have therapeutic potential. We now demonstrate that these antibodies bound with nM avidity to conformational epitopes on plate-immobilized synthetic A[beta] dimer assemblies, including synaptotoxic protofibrils, and targeted these conformers in solution. Importantly, NAbs also recognized A[beta] extracted from the water-soluble phase of human AD brain, including species that migrated on denaturing PAGE as SDS-stable dimers. The critical reliance on A[beta]'s conformational state for NAb binding, and not a linear sequence epitope, was confirmed by the antibody's nM reactivity with plate-immobilized protofibrills, and weak uM binding to synthetic A[beta] monomers and peptide fragments. The antibody's lack of reactivity against a linear sequence epitope was confirmed by our ability to isolate anti-A[beta] NAbs from intravenous immunoglobulin using affinity matrices, immunoglobulin light chain fibrils and Cibacron blue, which had no sequence similarity with the peptide. These findings suggest that further investigations on the molecular basis and the therapeutic/diagnostic potential of anti-A[beta] NAbs are warranted.